Deutsche Bank AG Has $126.98 Million Stock Position in Qiagen (NYSE:QGEN)

Deutsche Bank AG lifted its holdings in shares of Qiagen (NYSE:QGEN) by 25.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,851,510 shares of the company’s stock after purchasing an additional 573,269 shares during the period. Deutsche Bank AG owned 1.29% of Qiagen worth $126,978,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Brown Brothers Harriman & Co. bought a new stake in shares of Qiagen in the 4th quarter valued at $37,000. Geneos Wealth Management Inc. grew its holdings in Qiagen by 41.5% during the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock worth $38,000 after acquiring an additional 251 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Qiagen by 152.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock worth $39,000 after acquiring an additional 526 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Qiagen in the 3rd quarter valued at about $53,000. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Qiagen by 148.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company’s stock valued at $63,000 after purchasing an additional 835 shares during the period. Institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

Shares of NYSE QGEN opened at $41.87 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. The firm’s 50-day simple moving average is $40.67 and its 200 day simple moving average is $41.75. The stock has a market cap of $9.31 billion, a price-to-earnings ratio of 116.59, a PEG ratio of 2.39 and a beta of 0.67. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.05. The company had revenue of $483.46 million for the quarter, compared to analysts’ expectations of $465.66 million. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Qiagen’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.44 earnings per share. As a group, research analysts anticipate that Qiagen will post 2.26 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on QGEN. Baird R W downgraded Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. StockNews.com raised shares of Qiagen from a “buy” rating to a “strong-buy” rating in a research note on Friday. UBS Group decreased their price target on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Redburn Atlantic cut shares of Qiagen from a “buy” rating to a “neutral” rating in a research report on Friday, April 4th. Finally, Robert W. Baird raised their target price on Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. Seven research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $48.42.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.